Suárez, Cristina

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,791

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,260

Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a Phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma

Pal, S. K., Tannir, N. M., Grell, P., Gao, X., Kotecha, R. R., Picus, J., De Braud, F. G., Takahashi, S., Wong, A., Suárez, C., et al. (2024) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 9

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

Motzer, R. J., Park, S. H., McDermott, R. S., Porta, C., Heng, D. Y. C., Burotto, M., Iacovelli, R., Verzoni, E., Cutuli, H., Haanen, J., et al. (2026) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 9